Cravens & Co Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-1,286
| Closed | -$816K | – | 58 |
|
|
2025
Q1 | $816K | Buy |
1,286
+123
| +11% | +$78K | 0.63% | 34 |
|
|
2024
Q4 | $828K | Sell |
1,163
-142
| -11% | -$101K | 0.63% | 33 |
|
|
2024
Q3 | $1.37M | Buy |
1,305
+71
| +6% | +$74.6K | 1.06% | 16 |
|
|
2024
Q2 | $1.3M | Sell |
1,234
-57
| -4% | -$59.9K | 0.96% | 16 |
|
|
2024
Q1 | $1.24M | Buy |
1,291
+7
| +0.5% | +$6.74K | 1.03% | 19 |
|
|
2023
Q4 | $1.13M | Sell |
1,284
-16
| -1% | -$14.1K | 0.97% | 19 |
|
|
2023
Q3 | $1.07M | Buy |
1,300
+71
| +6% | +$58.4K | 1.01% | 17 |
|
|
2023
Q2 | $883K | Sell |
1,229
-10
| -0.8% | -$7.19K | 0.81% | 26 |
|
|
2023
Q1 | $1.02M | Sell |
1,239
-8
| -0.6% | -$6.57K | 0.95% | 17 |
|
|
2022
Q4 | $900K | Buy |
+1,247
| New | +$900K | 0.83% | 21 |
|